Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomedical Research | 1 | 2021 | 400 | 0.550 |
Why?
|
| Minority Groups | 1 | 2021 | 596 | 0.530 |
Why?
|
| Estrogens | 6 | 2012 | 202 | 0.440 |
Why?
|
| Pterocarpans | 5 | 2015 | 21 | 0.430 |
Why?
|
| Estrogen Receptor alpha | 9 | 2016 | 111 | 0.370 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2016 | 32 | 0.340 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2016 | 80 | 0.250 |
Why?
|
| Breast Neoplasms | 8 | 2017 | 1502 | 0.240 |
Why?
|
| Fundulidae | 2 | 2016 | 5 | 0.230 |
Why?
|
| DDT | 2 | 2012 | 15 | 0.210 |
Why?
|
| Butyrates | 1 | 2002 | 31 | 0.210 |
Why?
|
| Estrogen Antagonists | 3 | 2010 | 28 | 0.200 |
Why?
|
| Endocrine Disruptors | 2 | 2012 | 39 | 0.200 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 803 | 0.200 |
Why?
|
| Maryland | 1 | 2021 | 53 | 0.190 |
Why?
|
| Estradiol | 3 | 2012 | 262 | 0.190 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2011 | 31 | 0.190 |
Why?
|
| Receptors, Estrogen | 5 | 2011 | 156 | 0.190 |
Why?
|
| Cell Line, Tumor | 11 | 2017 | 2231 | 0.180 |
Why?
|
| Research Personnel | 1 | 2021 | 155 | 0.170 |
Why?
|
| Cell Proliferation | 7 | 2016 | 1198 | 0.170 |
Why?
|
| Response Elements | 4 | 2015 | 56 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 807 | 0.150 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2015 | 48 | 0.150 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 1015 | 0.150 |
Why?
|
| Plant Extracts | 3 | 2015 | 286 | 0.140 |
Why?
|
| Aptamers, Nucleotide | 1 | 2017 | 31 | 0.140 |
Why?
|
| Sterols | 1 | 2016 | 23 | 0.140 |
Why?
|
| Boronic Acids | 1 | 2016 | 19 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 409 | 0.140 |
Why?
|
| Humans | 22 | 2021 | 37093 | 0.140 |
Why?
|
| Isoflavones | 2 | 2010 | 129 | 0.140 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2015 | 28 | 0.130 |
Why?
|
| Signal Transduction | 6 | 2016 | 1908 | 0.130 |
Why?
|
| Isoenzymes | 3 | 2011 | 161 | 0.130 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2015 | 10 | 0.130 |
Why?
|
| Estrogen Receptor beta | 3 | 2010 | 40 | 0.130 |
Why?
|
| Coumarins | 1 | 2015 | 38 | 0.130 |
Why?
|
| Phenanthrenes | 1 | 2014 | 16 | 0.120 |
Why?
|
| Down-Regulation | 2 | 2016 | 435 | 0.120 |
Why?
|
| Phytoestrogens | 3 | 2010 | 38 | 0.120 |
Why?
|
| Regional Health Planning | 1 | 2013 | 14 | 0.120 |
Why?
|
| Sesquiterpenes | 2 | 2010 | 32 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 110 | 0.110 |
Why?
|
| Minority Health | 1 | 2013 | 88 | 0.110 |
Why?
|
| Sapogenins | 1 | 2012 | 3 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2017 | 318 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2012 | 85 | 0.100 |
Why?
|
| Environmental Pollutants | 1 | 2014 | 179 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 222 | 0.100 |
Why?
|
| Stereoisomerism | 4 | 2016 | 167 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 136 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 126 | 0.100 |
Why?
|
| Biomimetics | 1 | 2011 | 10 | 0.100 |
Why?
|
| Phenols | 1 | 2012 | 80 | 0.100 |
Why?
|
| Adamantane | 1 | 2010 | 8 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 74 | 0.090 |
Why?
|
| Phaseolus | 1 | 2010 | 15 | 0.090 |
Why?
|
| Transcription, Genetic | 5 | 2012 | 578 | 0.090 |
Why?
|
| Cell Survival | 5 | 2011 | 864 | 0.090 |
Why?
|
| Pyridines | 1 | 2010 | 116 | 0.090 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2009 | 19 | 0.090 |
Why?
|
| Terpenes | 1 | 2009 | 28 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 65 | 0.080 |
Why?
|
| MAP Kinase Kinase 5 | 1 | 2008 | 4 | 0.080 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2009 | 62 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2008 | 8 | 0.080 |
Why?
|
| Flavonols | 1 | 2008 | 16 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 560 | 0.080 |
Why?
|
| Fermentation | 1 | 2008 | 26 | 0.080 |
Why?
|
| Structure-Activity Relationship | 3 | 2016 | 409 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 494 | 0.080 |
Why?
|
| Mesoderm | 1 | 2008 | 70 | 0.080 |
Why?
|
| Epithelium | 1 | 2008 | 79 | 0.080 |
Why?
|
| Animals | 9 | 2016 | 15081 | 0.080 |
Why?
|
| Female | 10 | 2017 | 20969 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2013 | 642 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 356 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2012 | 426 | 0.070 |
Why?
|
| Proteomics | 1 | 2008 | 325 | 0.070 |
Why?
|
| Bufanolides | 1 | 2006 | 2 | 0.070 |
Why?
|
| Pre-Eclampsia | 1 | 2006 | 61 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 623 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 502 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2011 | 859 | 0.060 |
Why?
|
| Neoplasms | 1 | 2013 | 1103 | 0.060 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2003 | 19 | 0.060 |
Why?
|
| Tamoxifen | 2 | 2016 | 65 | 0.060 |
Why?
|
| Fabaceae | 1 | 2003 | 27 | 0.060 |
Why?
|
| Luciferases | 2 | 2015 | 63 | 0.050 |
Why?
|
| Molecular Mimicry | 1 | 2002 | 16 | 0.050 |
Why?
|
| Genes, Reporter | 2 | 2015 | 136 | 0.050 |
Why?
|
| Biotransformation | 1 | 2002 | 67 | 0.050 |
Why?
|
| Models, Chemical | 2 | 2015 | 207 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2002 | 105 | 0.050 |
Why?
|
| Models, Molecular | 3 | 2010 | 808 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2010 | 1518 | 0.050 |
Why?
|
| Cell Line | 3 | 2010 | 1354 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 172 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2015 | 928 | 0.040 |
Why?
|
| Mice | 4 | 2012 | 5913 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2010 | 337 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2010 | 259 | 0.040 |
Why?
|
| Hypertension | 1 | 2006 | 796 | 0.040 |
Why?
|
| Rats | 2 | 2006 | 3483 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 626 | 0.040 |
Why?
|
| Gene Expression | 2 | 2010 | 674 | 0.040 |
Why?
|
| Excipients | 1 | 2017 | 22 | 0.040 |
Why?
|
| Biological Availability | 1 | 2016 | 88 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 245 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 215 | 0.030 |
Why?
|
| Liposomes | 1 | 2017 | 118 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 151 | 0.030 |
Why?
|
| Molecular Structure | 2 | 2009 | 492 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 224 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2017 | 133 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2011 | 421 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 92 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 202 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 997 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2014 | 33 | 0.030 |
Why?
|
| Toxicity Tests | 1 | 2014 | 43 | 0.030 |
Why?
|
| Methylation | 1 | 2014 | 113 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 59 | 0.030 |
Why?
|
| Ligands | 1 | 2015 | 349 | 0.030 |
Why?
|
| Drug Design | 1 | 2015 | 162 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2013 | 49 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2013 | 38 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 708 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 1568 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 269 | 0.030 |
Why?
|
| Community Networks | 1 | 2013 | 108 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2014 | 206 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 935 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2013 | 170 | 0.030 |
Why?
|
| Insecticides | 1 | 2012 | 51 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 114 | 0.030 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 43 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 1609 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 113 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 448 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 81 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 289 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 212 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 260 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 122 | 0.020 |
Why?
|
| Fruit | 1 | 2010 | 173 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2008 | 21 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 389 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2013 | 1378 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 550 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2008 | 111 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 78 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 362 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 112 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 189 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 893 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 142 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 651 | 0.020 |
Why?
|
| Glucose | 1 | 2009 | 230 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 312 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 182 | 0.020 |
Why?
|
| Ouabain | 1 | 2006 | 15 | 0.020 |
Why?
|
| Phenotype | 1 | 2008 | 689 | 0.020 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2006 | 28 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 677 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1207 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 433 | 0.010 |
Why?
|
| Methanol | 1 | 2003 | 18 | 0.010 |
Why?
|
| Plant Preparations | 1 | 2003 | 27 | 0.010 |
Why?
|
| Male | 2 | 2012 | 20025 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 153 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 307 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 646 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 523 | 0.010 |
Why?
|
| Pregnancy | 1 | 2006 | 1549 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 1371 | 0.010 |
Why?
|
| Kidney | 1 | 2003 | 337 | 0.010 |
Why?
|